Valneva SE (VALN) stock

VALNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 20-F on Mar 17, 2026Score 1/30

$5.66−0.10 (-1.74%)

Close on Nov 13, 2026Market cap $491.12MP/E –Yield –

Valneva ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

For fiscal 2025 it was -€60.31M, down 283.2% from the year before. The highest annual figure on record is €32.92M in fiscal 2024.

Period	Period end	Value	Change
FY2025	Dec 31, 2025	-€60.31M	-283.2%
FY2024	Dec 31, 2024	€32.92M	–
FY2023	Dec 31, 2023	-€64.50M	–
FY2022	Dec 31, 2022	-€92.41M	–
FY2021	Dec 31, 2021	-€47.11M	–
FY2020	Dec 31, 2020	-€45.32M	–

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is VALN.

Revenue growth-27.2% · median 25.4%

Gross margin16.4% · median 89.0%

Operating margin-80.5% · median -21.2%

Advertisement
300 × 250

See a number that looks wrong?